NICE rejects Pfizer’s rare heart disease treatment Vyndaqel
The final guidance publication comes following an appeal against earlier draft recommendations
Read More
Tag: Vyndaqel
Vyndaqel first treatment approved in Europe for ATTR-CM
The decision was based on results from the Phase III ATTR-ACT study.
Read More
Pfizer’s Vyndaqel, Vyndamax win US nod for rare disease
The approval is based on a clinical trial which showed that after an average of 30 months, the survival rate was higher in the Vyndaqel group.
Read More
Pfizer’s Vyndaqel slows neurodegenerative disease, analysis shows
A new analysis of data pooled from three clinical trials backs early intervention with Pfizer’s Vyndaqel in patients with the rare neurodegenerative disease transthyretin familial amyloid polyneuropathy (TTR-FAP).
Read More
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
